Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

Investors can expect a post-close release and likely an associated investor webcast or call timing to be announced separately by the company.

Key Figures

Earnings release date: February 24, 2026

1 metrics

Earnings release date February 24, 2026 Scheduled Q4 and full-year 2025 results release after U.S. market close

Market Reality Check

Price: $1.24 Vol: Volume of 881,405 is at 0...

normal vol

$1.24 Last Close

Volume Volume of 881,405 is at 0.78x the 20-day average of 1,133,051. normal

Technical Shares at $1.26 are trading below the 200-day moving average of $1.29 and 26.74% below the 52-week high.

Peers on Argus

LAB was flat ahead of the earnings date news, while close peers showed mixed mov...

LAB was flat ahead of the earnings date news, while close peers showed mixed moves: BVS -5.65%, CTKB -0.78%, AVNS -1.45%, and KIDS +0.42%, suggesting no clear sector-wide direction.

Historical Context

5 past events · Latest: Jan 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 30	Asset sale completion	Positive	-0.7%	Completed SomaLogic sale to Illumina with substantial cash proceeds and royalties.
Jan 08	Prelim revenue update	Positive	+20.3%	Preliminary Q4 and FY2025 revenue and cash outlook for continuing operations.
Nov 19	Strategic collaboration	Positive	+3.2%	Collaboration to integrate HCR imaging with Hyperion Imaging System for IMC.
Nov 10	Partner product update	Positive	+3.5%	Illumina update including definitive agreement to acquire SomaLogic from LAB.
Nov 04	Quarterly earnings	Neutral	-4.0%	Q3 2025 results with revenue decline but cost savings and EBITDA targets.

Pattern Detected

Recent news with clearly positive fundamentals has sometimes produced muted or negative next-day moves, while preliminary revenue updates saw a strong positive reaction.

Recent Company History

Over the last several months, Standard BioTools announced multiple strategic and financial milestones. An early January update guided to ~$56M in Q4 2025 combined revenue and ~$185M for full-year combined revenue, which was followed by a 20.31% gain. The subsequent completion of the SomaLogic sale, with expected cash of about $550M, saw a modest -0.71% move. Earlier, Q3 2025 results showed $19.6M in revenue from continuing operations and an operational restructuring targeting over $40M in annualized cost savings. Today’s earnings date notice fits into this ongoing transition and reporting cycle.

Market Pulse Summary

This announcement sets the timing for Standard BioTools’ fourth quarter and full year 2025 results o...

Analysis

This announcement sets the timing for Standard BioTools’ fourth quarter and full year 2025 results on February 24, 2026. In recent months, the company has issued preliminary revenue figures, reported Q3 performance, and completed the sale of SomaLogic, all against a backdrop of cost actions and a target for positive adjusted EBITDA in 2026. Investors may focus on final audited numbers, updated cash balances following the divestiture, and any refreshed outlook for the remaining mass cytometry and microfluidics businesses.

AI-generated analysis. Not financial advice.

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2026 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com

FAQ

When will Standard BioTools (LAB) report fourth quarter and full year 2025 results?

The company will publish results on February 24, 2026 after U.S. market close. According to Standard BioTools, the release covers fourth quarter and full year 2025 financial results and will be available after markets close that day.

Will Standard BioTools (LAB) hold an earnings call or webcast on February 24, 2026?

A call or webcast is not specified in the announcement; check investor relations for updates. According to Standard BioTools, details about any earnings call or webcast will be provided separately if scheduled.

How should investors prepare for Standard BioTools (LAB) results on February 24, 2026?

Monitor the post-close release and be ready for potential after-hours stock movement following the announcement. According to Standard BioTools, the company will release full year and Q4 2025 results after market close, which can influence after-hours trading.

Where can I find the Standard BioTools (LAB) February 24, 2026 earnings release?

Look on the company's investor relations page and SEC filings after the market close on February 24, 2026. According to Standard BioTools, the fourth quarter and full year 2025 results will be published after U.S. market close that day.

Will Standard BioTools (LAB) provide guidance with the February 24, 2026 results?

The announcement does not state whether guidance will be provided with the release; check the report itself for guidance language. According to Standard BioTools, the company will publish Q4 and full year 2025 results on February 24, 2026.

How might after-hours timing affect LAB stock when results are released on February 24, 2026?

Releasing results after U.S. market close can lead to immediate after-hours price moves and overnight reassessment by investors. According to Standard BioTools, results will be released after the close on February 24, 2026, possibly affecting after-hours trading.